Reprotech and TMRW are combining, bringing together two leaders in cryostorage and technology, to deliver an integrated digital solution for frozen specimens.

Update for our Clinic and Lab Partners

Reprotech and TMRW Life Sciences have entered into a strategic business combination to create the industry’s most comprehensive, technology-enabled company for the management and cryostorage of frozen eggs, embryos, and sperm.

The combined business will operate under the Reprotech banner, which will now feature the TMRW, Matcher, and Cryologix brands.

What’s coming together—and what it enables

This strategic combination couples Reprotech’s 35+ years of cryostorage leadership with TMRW’s next-generation technology to deliver a fully integrated digital solution for frozen eggs, embryos, and sperm at scale.

Reprotech brings:

• More than 35 years of leadership in long-term cryostorage
• A national network of offsite biorepositories
• Established digital witnessing and billing platforms, including Matcher and Cryologix
• Partnerships with a large variety of clinics, hospitals, and universities.

TMRW contributes:

• Its Digital Specimen Management platform
• Advanced automated and manual storage solutions
• Commercial partnerships with leading fertility networks

Together, these complementary strengths across technology, operations, and clinical partnerships create a complete digital solution for the tracking, management, and storage of frozen eggs, embryos, and sperm.

Leadership for the combined organization

As part of the business combination:

• Louis Villalba, former Chief Executive Officer of TMRW Life Sciences, serves as the Chief Executive Officer of the combined organization.
• Brad Senstra, former Chief Executive Officer of Reprotech, serves as the Chief Operating Officer.

Scale and national reach

The combined organization will:

• Safeguard more than one million fertility specimens
• Partner with approximately 75% of fertility centers nationwide
• Support more than 50% of U.S. patient cycles
• Operate eight offsite storage facilities

Meeting the moment as frozen volumes grow

As the fertility industry continues shifting from fresh to frozen cycles, clinics are managing cryostorage volumes far beyond what much of their original infrastructure was designed to support. This trend is increasing demand for storage solutions that can scale safely, accurately, and efficiently.

With complementary strengths across technology, operations, and clinical partnerships, the combined organization is well positioned to support the evolving needs of fertility clinics and patients across the United States, with the opportunity to expand internationally over time.

What this means for clinic partners (and the patients you serve)

The combined organization supports a broad range of fertility clinics, health systems, and patient populations nationwide. Reprotech partners with leading university and hospital-based fertility centers, fertility preservation centers, and many independent fertility practices, while TMRW works with some of the largest fertility networks in the country.

This business combination strengthens the combined company’s national reach and expands its ability to provide clinics and patients with a unified, flexible solution across both onsite and offsite storage environments.

Throughout the integration process, clinic partners and patients can expect continuity of care, clear communication, expanded digital capabilities, and continued investment in safety, service, and innovation. With a shared commitment to patient safety, regulatory excellence, and continuous innovation, the combined organization is poised to set a new standard for fertility cryostorage.

What our leaders are saying

Luis A. Fernandez, Chairman of the Board of Reprotech

“There is clear industrial logic in bringing Reprotech and TMRW together,” said Luis A. Fernandez, Chairman of the Board of Reprotech. “We are building a company designed to meet the evolving demands of the fertility industry by combining state of the art infrastructure, trusted service, and next-generation technology. Following our investment in IMT Matcher and now with TMRW’s Digital Specimen Management platform, we are creating a fully technology-enabled cryostorage offering that can meet clinics where they are today while helping define where the industry is going tomorrow.”

Louis Villalba, Chief Executive Officer of the combined organization

“At TMRW, our mission has always been to safeguard life’s most precious cells and advance the standard of care,” said Louis Villalba, Chief Executive Officer of the combined organization. “By joining forces with Reprotech, we have the opportunity to bring together trusted infrastructure, national scale, and digital innovation in a way that is truly differentiated in the fertility market. I’m excited to lead this next chapter and help build the future of fertility cryostorage.”

Brad Senstra, Chief Operating Officer of the combined company

“With the combined resources of Reprotech and TMRW, we are now able to accelerate the technology and products we offer our partners,” said Brad Senstra, Chief Operating Officer of the combined company. “We are moving forward with a truly talented team that will make specimen management safer, streamlined, and more cost-effective for fertility clinics and their patients.”

Read the official press release

For full details and the complete announcement, read the official press release.

About Reprotech

Reprotech is the leading provider of products and services for the safe-guarding, management and long-term storage of reproductive specimens. Reprotech’s integrated portfolio includes five purpose-built biorepositories across the U.S., advanced cryostorage management technologies and global digital chain-of-custody solutions. Reprotech partners with fertility centers to reduce specimen storage burden and liability, streamline billing and consent management, strengthen traceability, and manage risk. Built on decades of experience and driven by continuous innovation, Reprotech’s rigorous compliance standards and operational excellence set the benchmark for protecting specimens from clinic to cryostorage, ensuring customers have secure options for preserving what matters most, today and for the future.

About TMRW Life Sciences

Founded in 2018, TMRW Life Sciences, Inc. is a fertility technology company digitizing the IVF lab with the world’s first automated platform for the safe management and storage of frozen sperm, eggs, and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW’s next-generation technology platforms set a new standard of care by reducing potential points of failure associated with manual systems. Named Fast Company’s #1 Most Innovative Biotech Company in 2022, TMRW has been adopted by leading fertility clinics across the United States and United Kingdom.